TScan Therapeutics (TCRX) Cash from Investing Activities (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Cash from Investing Activities data on file, last reported at -$70000.0 in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 100.52% year-over-year to -$70000.0 in Q1 2026; TTM through Mar 2026 was $95.8 million, a 227.28% increase from a year earlier, with the FY2025 full-year figure at $109.4 million, up 307.88% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$70000.0, down from $14.8 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for TCRX reached as high as $48.4 million in Q2 2025 and fell as low as -$82.4 million in Q3 2024.
• Historically, Cash from Investing Activities has averaged -$487941.2 across 5 years, with a median of -$420000.0 in 2023.
• Across the five-year window, Cash from Investing Activities plunged 14384.43% in 2023 and jumped 4415.39% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at -$1.4 million in 2022, then soared by 238.93% to $1.9 million in 2023, then jumped by 1326.71% to $27.3 million in 2024, then sank by 45.67% to $14.8 million in 2025, then slumped by 100.47% to -$70000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$70000.0 in Q1 2026, $14.8 million in Q4 2025, and $32.6 million in Q3 2025.